OTCMKTS:ENZN Enzon Pharmaceuticals (ENZN) Stock Price, News & Analysis → Top-Secret Government Project Revealed (From Porter & Company) (Ad) Free ENZN Stock Alerts $0.15 -0.03 (-16.67%) (As of 06/13/2024 ET) Add Compare Share Share Today's Range$0.15▼$0.1750-Day Range$0.06▼$0.2352-Week Range$0.06▼$0.24Volume21,390 shsAverage Volume31,095 shsMarket Capitalization$11.13 millionP/E Ratio15.02Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsSEC FilingsShort Interest Get Enzon Pharmaceuticals alerts: Email Address Enzon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.04% of Shares Sold ShortDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment-0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.17 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Enzon Pharmaceuticals.Read more about Enzon Pharmaceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.04% of the outstanding shares of Enzon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEnzon Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Enzon Pharmaceuticals has recently increased by 1,568.75%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEnzon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnzon Pharmaceuticals does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of Enzon Pharmaceuticals is 1,200.00%. Payout ratios above 75% are not desirable because they may not be sustainable.Read more about Enzon Pharmaceuticals' dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ENZN. Previous Next 1.4 News and Social Media Coverage News SentimentEnzon Pharmaceuticals has a news sentiment score of -0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Enzon Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows4 people have added Enzon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enzon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.27% of the stock of Enzon Pharmaceuticals is held by insiders.Read more about Enzon Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Enzon Pharmaceuticals is 15.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.30.Price to Earnings Ratio vs. SectorThe P/E ratio of Enzon Pharmaceuticals is 15.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 167.79. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Freeport SocietyDemocrats’ “break glass for emergency” candidate for 2024Nate Silver has been a celebrity pundit since at least the 2008 election, when he correctly predicted the winner in 49 of 50 states, and nailed all 35 Senate election outcomes. But interestingly, one man reached the same conclusion as Nate Silver a long time ago…For full details, click here. About Enzon Pharmaceuticals Stock (OTCMKTS:ENZN)Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.Read More ENZN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ENZN Stock News HeadlinesJune 14 at 2:16 AM | americanbankingnews.comEnzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) Short Interest Up 1,568.8% in MayJune 8, 2024 | americanbankingnews.comReviewing Enzon Pharmaceuticals (OTCMKTS:ENZN) and Genenta Science (NASDAQ:GNTA)June 4, 2024 | americanbankingnews.comPalisade Bio (NASDAQ:PALI) & Enzon Pharmaceuticals (OTCMKTS:ENZN) Critical ComparisonNovember 8, 2023 | morningstar.comEnzon Pharmaceuticals Inc ENZNOctober 25, 2023 | finance.yahoo.comOKYO Pharma Limited (OK10.F)July 30, 2023 | nasdaq.comRegeneron Pharmaceuticals, Inc. Common Stock (REGN)March 26, 2023 | thestreet.comEnzon Stock Hits New 52-Week Low (ENZN)March 20, 2023 | investing.comIbnsina Pharma Co (ISPH)February 26, 2023 | time.comBig Pharma’s Patent Abuses Are Fueling the Drug Pricing CrisisJuly 15, 2022 | morningstar.comEnzon Pharmaceuticals Inc - Stock Operating Performance ENZNJuly 2, 2022 | finance.yahoo.comEnzon Pharmaceuticals, Inc. (ENZN)See More Headlines Receive ENZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enzon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/20/2024Today6/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CUSIP29390410 CIK727510 Webwww.enzon.com Phone(732) 980-4500Fax732-980-4585EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.01 Trailing P/E Ratio15.02 Forward P/E RatioN/A P/E GrowthN/ANet Income$1.37 million Net MarginsN/A Pretax Margin3,573.08% Return on Equity49.71% Return on Assets3.18% Debt Debt-to-Equity RatioN/A Current Ratio89.19 Quick Ratio89.19 Sales & Book Value Annual Sales$30,000.00 Price / Sales371.10 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares74,220,000Free FloatN/AMarket Cap$11.13 million OptionableNot Optionable Beta0.51 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Richard L. Feinstein CPA (Age 81)CEO, CFO & Secretary Comp: $224.07kKey CompetitorsCurisNASDAQ:CRISFortress BiotechNASDAQ:FBIOBolt BiotherapeuticsNASDAQ:BOLTSAB BiotherapeuticsNASDAQ:SABSMolecular TemplatesNASDAQ:MTEMView All Competitors ENZN Stock Analysis - Frequently Asked Questions How have ENZN shares performed in 2024? Enzon Pharmaceuticals' stock was trading at $0.0936 on January 1st, 2024. Since then, ENZN stock has increased by 60.3% and is now trading at $0.15. View the best growth stocks for 2024 here. Are investors shorting Enzon Pharmaceuticals? Enzon Pharmaceuticals saw a increase in short interest in May. As of May 31st, there was short interest totaling 26,700 shares, an increase of 1,568.8% from the May 15th total of 1,600 shares. Based on an average daily trading volume, of 119,100 shares, the days-to-cover ratio is presently 0.2 days. View Enzon Pharmaceuticals' Short Interest. How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals, Inc. (OTCMKTS:ENZN) announced its quarterly earnings results on Wednesday, March, 20th. The biotechnology company reported $0.01 EPS for the quarter. Is Enzon Pharmaceuticals a good dividend stock? Enzon Pharmaceuticals (OTCMKTS:ENZN) pays an annual dividend of $0.12 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 1,200.00%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for ENZN. What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Aeterna Zentaris (AEZS), CBL & Associates Properties (CBL), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Golar LNG Partners (GMLP), Washington Prime Group (WPG), DHT (DHT), Hallador Energy (HNRG) and Medical Marijuana (MJNA). How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:ENZN) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersGold Prices Surge and This $0.32 Stock Is Reaping The RewardsGold prices are on the rise. This surge in gold prices is great news for gold mining stocks. Especially ...Market JAR | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredLike Investing in Big Tech in the Early 2000s?More than a decade after the first Bitcoin was mined, people are finally realizing something very important......Manward Press | SponsoredThe Single Biggest Breakthrough of the Decade Billionaires, Jeff Bezos, Bill Gates, Warren Buffett, and Sir Richard Branson are rallying behind this technol...Porter & Company | SponsoredAn utter travestyThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enzon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enzon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.